This afternoon we watched Novo Nordisk A/S drop -4.3% to a price of $56.19 per share. The Large-Cap Pharmaceutical company is now trading -8.14% below its average target price of $61.17. Analysts have set target prices ranging from $49.224285 to $70.68026 per share for Novo Nordisk A/S, and have given the stock an average rating of buy.
The stock has a very low short interest at 0.8%, and a short ratio of 0.96. At 0.01%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a very small number of institutional investors are invested in the stock, with 9.4% of Novo Nordisk A/S's shares being owned by this investor type.
Institutions Invested in Novo Nordisk A/S
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Jennison Associates LLC | 1% | 18,885,343 | $1,061,165,524 |
| 2025-06-30 | Bank of America Corporation | 0% | 14,721,478 | $827,198,368 |
| 2025-06-30 | Morgan Stanley | 0% | 14,284,790 | $802,660,913 |
| 2025-06-30 | FMR, LLC | 0% | 13,941,160 | $783,352,378 |
| 2025-06-30 | LOOMIS SAYLES & CO L P | 0% | 12,576,031 | $706,645,917 |
| 2025-06-30 | Capital International Investors | 0% | 11,621,232 | $652,995,857 |
| 2025-06-30 | Fisher Asset Management, LLC | 0% | 11,000,916 | $618,140,363 |
| 2025-06-30 | Sarofim, Fayez & Co | 0% | 10,503,662 | $590,199,711 |
| 2025-06-30 | Folketrygdfondet | 0% | 10,094,543 | $567,211,356 |
| 2025-06-30 | ClearBridge Investments, LLC | 0% | 8,222,673 | $462,031,169 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Novo Nordisk A/S.
